To what extent do spinal interactions between an alpha-2 adrenoceptor agonist and a mu opioid agonist influence noxiously evoked c-Fos expression in the rat? A pharmacological study.
Three hours after the intraplantar injection of carrageenin (6 mg/150 microliters of saline) Fos-like immunoreactivity (Fos-LI) was observed in both superficial and deep laminae of the dorsal horn segments L4 and L5 of the spinal cord. Systemic medetomidine, an alpha-2 adrenoceptor agonist (12.5, 25 or 75 micrograms/kg i.v.), dose-dependently reduced the number of superficial and deep Fos-LI neurons; 75 micrograms/kg produced a 66 +/- 4% and a 90 +/- 4% reduction of superficial and deep Fos-LI neurons, respectively, P < .0001 for both. In addition, systemic medetomidine dose-relatedly reduced the carrageenin-evoked paw and ankle edema; medetomidine 75 micrograms/kg resulted in a 70 +/- 3% reduction of paw edema and in a blockade of the development of ankle edema. The effects of medetomidine were blocked by systemic atipamezole (75 micrograms/kg, i.v.), which, when injected alone, had no effect on the number of Fos-LI neurons or the peripheral edema. Co-administration of a low dose of medetomidine (12.5 micrograms/kg i.v.) with an ineffective dose of morphine (1.5 micrograms/kg i.v.) strongly decreased the number of superficial and deep Fos-LI neurons (40 +/- 5%, P < .0001 and 62 +/- 11%, P < .0001 reduction as compared with control group) without altering the effects of medetomidine on the peripheral edema. Both atipamezole and a combined injection of atipamezole and naloxone blocked the effects of medetomidine plus morphine on both the total number of Fos-LI neurons (86 +/- 11% and 86 +/- 6% of control, respectively) and carrageenin inflammation (87 +/- 6%, P < .05 and 84 +/- 3%, P < .05 of control for the paw edema; 75 +/- 8%, P < .01 and 81 +/- 7%, P < .05 of control for the ankle edema, respectively). Naloxone alone blocked the effects of the co-administered agonists on the total number of Fos-Li neurons (91 +/- 6% of the control carrageenin group) without influencing the effect on the peripheral edema. Our results demonstrate, for the first time, that co-administration of alpha-2 adrenoceptor and mu opioid agonists substantially reduces inflammatory evoked expression of c-Fos, one of the long-term consequences of sustained nociceptive processing.
Honoré
P
P
Physiopharmacologie du Système Nerveux, Paris, France.
Chapman
V
V
Buritova
J
J
Besson
J M
JM
D058647:Adrenergic alpha-2 Receptor Agonists; D000316:Adrenergic alpha-Agonists / Q000494:pharmacology*; D000818:Animals; D004305:Dose-Response Relationship, Drug; D015870:Gene Expression / Q000187:drug effects*; D007093:Imidazoles / Q000494:pharmacology*; D007150:Immunohistochemistry; D008297:Male; D020926:Medetomidine; D009020:Morphine / Q000494:pharmacology; D016760:Proto-Oncogene Proteins c-fos / Q000096:biosynthesis*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017450:Receptors, Opioid, mu / Q000819:agonists*
D058647:Adrenergic alpha-2 Receptor Agonists; D000316:Adrenergic alpha-Agonists; D007093:Imidazoles; D016760:Proto-Oncogene Proteins c-fos; D017450:Receptors, Opioid, mu; D009020:Morphine; D020926:Medetomidine